SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/17.01.25

SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/17.01.25 Share Price

DE000SY01C98

Market Closed - Bid/Ask 07:32:53 03/07/2024 BST			After market 19:13:02
2.2 ^EUR	-5.17%		2.35	+6.82%

Current month	+2.20%
1 month	-34.46%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart SG/PUT/VERTEX PHARMACEUTICALS/450/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
03/07/24	2.2	-5.17%
02/07/24	2.32	-2.11%
01/07/24	2.37	+4.41%
28/06/24	2.27	+0.44%
27/06/24	2.26	-3.00%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 07:32 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Société Générale
WKN	SY01C9
ISIN	DE000SY01C98
Date issued	29/05/2024
Strike	450 $
Maturity	17/01/2025 (198 Days)
Parity	10 : 1
Emission price	2.99 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	3.65 €
Lowest since issue	2.13 €
Delta	-0.33x
Omega	6.068
Premium	9.72x
Gearing	18.48x
Moneyness	0.9569
Difference Strike	-20.28 $
Difference Strike %	-4.51%
Spread	0.14 €
Spread %	5.76%
Theoretical value	2.350
Implied Volatility	30.00 %
Total Loss Probability	58.87 %
Intrinsic value	0.000000
Present value	2.350
Break even	424.66 €
Theta	-0.04x
Vega	0.12x
Rho	-0.09x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.8 USD

Average target price

468.3 USD

Spread / Average Target

-1.16%

Consensus